

Global Cardiometabolic Disease Drug Market Growth 2024-2030

<https://marketpublishers.com/r/G339A3A62116EN.html>

Date: July 2024

Pages: 132

Price: US\$ 3,660.00 (Single User License)

ID: G339A3A62116EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Cardiometabolic Disease Drug market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Cardiometabolic Disease Drug Industry Forecast” looks at past sales and reviews total world Cardiometabolic Disease Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Cardiometabolic Disease Drug sales for 2024 through 2030. With Cardiometabolic Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cardiometabolic Disease Drug industry.

This Insight Report provides a comprehensive analysis of the global Cardiometabolic Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cardiometabolic Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cardiometabolic Disease Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardiometabolic Disease Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-

up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardiometabolic Disease Drug.

United States market for Cardiometabolic Disease Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Cardiometabolic Disease Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Cardiometabolic Disease Drug is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Cardiometabolic Disease Drug players cover Merck, Roche Holding AG, Servier, Qilu Pharmaceutical, Sydler Group, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Cardiometabolic Disease Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Trimetazidine

L-carnitine

Cyclic Adenosine Monophosphate

Coenzyme Q10

Others

Segmentation by Application:

Online Sales

Hospital

Clinic

Retail Pharmacy

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Merck

Roche Holding AG

Servier

Qilu Pharmaceutical

Sydler Group

Taj Pharma

Abbott

Chengda Pharmaceutical

Lonza Group

Hengtai Chemical

Northeast Pharmaceutical

Biosint

NHU

Kingdomway

Kaneka

Space Biology

ZMC

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cardiometabolic Disease Drug market?

What factors are driving Cardiometabolic Disease Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Cardiometabolic Disease Drug market opportunities vary by end market size?

How does Cardiometabolic Disease Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Cardiometabolic Disease Drug Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Cardiometabolic Disease Drug by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Cardiometabolic Disease Drug by Country/Region, 2019, 2023 & 2030

2.2 Cardiometabolic Disease Drug Segment by Type

- 2.2.1 Trimetazidine
- 2.2.2 L-carnitine
- 2.2.3 Cyclic Adenosine Monophosphate
- 2.2.4 Coenzyme Q10
- 2.2.5 Others

2.3 Cardiometabolic Disease Drug Sales by Type

- 2.3.1 Global Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)
- 2.3.2 Global Cardiometabolic Disease Drug Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Cardiometabolic Disease Drug Sale Price by Type (2019-2024)

2.4 Cardiometabolic Disease Drug Segment by Application

- 2.4.1 Online Sales
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Retail Pharmacy
- 2.4.5 Others

2.5 Cardiometabolic Disease Drug Sales by Application

2.5.1 Global Cardiometabolic Disease Drug Sale Market Share by Application (2019-2024)

2.5.2 Global Cardiometabolic Disease Drug Revenue and Market Share by Application (2019-2024)

2.5.3 Global Cardiometabolic Disease Drug Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Cardiometabolic Disease Drug Breakdown Data by Company

3.1.1 Global Cardiometabolic Disease Drug Annual Sales by Company (2019-2024)

3.1.2 Global Cardiometabolic Disease Drug Sales Market Share by Company (2019-2024)

3.2 Global Cardiometabolic Disease Drug Annual Revenue by Company (2019-2024)

3.2.1 Global Cardiometabolic Disease Drug Revenue by Company (2019-2024)

3.2.2 Global Cardiometabolic Disease Drug Revenue Market Share by Company (2019-2024)

3.3 Global Cardiometabolic Disease Drug Sale Price by Company

3.4 Key Manufacturers Cardiometabolic Disease Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Cardiometabolic Disease Drug Product Location Distribution

3.4.2 Players Cardiometabolic Disease Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CARDIOMETABOLIC DISEASE DRUG BY GEOGRAPHIC REGION

4.1 World Historic Cardiometabolic Disease Drug Market Size by Geographic Region (2019-2024)

4.1.1 Global Cardiometabolic Disease Drug Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Cardiometabolic Disease Drug Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Cardiometabolic Disease Drug Market Size by Country/Region (2019-2024)

4.2.1 Global Cardiometabolic Disease Drug Annual Sales by Country/Region

(2019-2024)

4.2.2 Global Cardiometabolic Disease Drug Annual Revenue by Country/Region

(2019-2024)

4.3 Americas Cardiometabolic Disease Drug Sales Growth

4.4 APAC Cardiometabolic Disease Drug Sales Growth

4.5 Europe Cardiometabolic Disease Drug Sales Growth

4.6 Middle East & Africa Cardiometabolic Disease Drug Sales Growth

5 AMERICAS

5.1 Americas Cardiometabolic Disease Drug Sales by Country

5.1.1 Americas Cardiometabolic Disease Drug Sales by Country (2019-2024)

5.1.2 Americas Cardiometabolic Disease Drug Revenue by Country (2019-2024)

5.2 Americas Cardiometabolic Disease Drug Sales by Type (2019-2024)

5.3 Americas Cardiometabolic Disease Drug Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Cardiometabolic Disease Drug Sales by Region

6.1.1 APAC Cardiometabolic Disease Drug Sales by Region (2019-2024)

6.1.2 APAC Cardiometabolic Disease Drug Revenue by Region (2019-2024)

6.2 APAC Cardiometabolic Disease Drug Sales by Type (2019-2024)

6.3 APAC Cardiometabolic Disease Drug Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Cardiometabolic Disease Drug by Country

7.1.1 Europe Cardiometabolic Disease Drug Sales by Country (2019-2024)

- 7.1.2 Europe Cardiometabolic Disease Drug Revenue by Country (2019-2024)
- 7.2 Europe Cardiometabolic Disease Drug Sales by Type (2019-2024)
- 7.3 Europe Cardiometabolic Disease Drug Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Cardiometabolic Disease Drug by Country
 - 8.1.1 Middle East & Africa Cardiometabolic Disease Drug Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Cardiometabolic Disease Drug Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Cardiometabolic Disease Drug Sales by Type (2019-2024)
- 8.3 Middle East & Africa Cardiometabolic Disease Drug Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Cardiometabolic Disease Drug
- 10.3 Manufacturing Process Analysis of Cardiometabolic Disease Drug
- 10.4 Industry Chain Structure of Cardiometabolic Disease Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Cardiometabolic Disease Drug Distributors

11.3 Cardiometabolic Disease Drug Customer

12 WORLD FORECAST REVIEW FOR CARDIOMETABOLIC DISEASE DRUG BY GEOGRAPHIC REGION

12.1 Global Cardiometabolic Disease Drug Market Size Forecast by Region

12.1.1 Global Cardiometabolic Disease Drug Forecast by Region (2025-2030)

12.1.2 Global Cardiometabolic Disease Drug Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Cardiometabolic Disease Drug Forecast by Type (2025-2030)

12.7 Global Cardiometabolic Disease Drug Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Merck

13.1.1 Merck Company Information

13.1.2 Merck Cardiometabolic Disease Drug Product Portfolios and Specifications

13.1.3 Merck Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Merck Main Business Overview

13.1.5 Merck Latest Developments

13.2 Roche Holding AG

13.2.1 Roche Holding AG Company Information

13.2.2 Roche Holding AG Cardiometabolic Disease Drug Product Portfolios and Specifications

13.2.3 Roche Holding AG Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Roche Holding AG Main Business Overview

13.2.5 Roche Holding AG Latest Developments

13.3 Servier

- 13.3.1 Servier Company Information
- 13.3.2 Servier Cardiometabolic Disease Drug Product Portfolios and Specifications
- 13.3.3 Servier Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Servier Main Business Overview
- 13.3.5 Servier Latest Developments
- 13.4 Qilu Pharmaceutical
 - 13.4.1 Qilu Pharmaceutical Company Information
 - 13.4.2 Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.4.3 Qilu Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Qilu Pharmaceutical Main Business Overview
 - 13.4.5 Qilu Pharmaceutical Latest Developments
- 13.5 Sydler Group
 - 13.5.1 Sydler Group Company Information
 - 13.5.2 Sydler Group Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.5.3 Sydler Group Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Sydler Group Main Business Overview
 - 13.5.5 Sydler Group Latest Developments
- 13.6 Taj Pharma
 - 13.6.1 Taj Pharma Company Information
 - 13.6.2 Taj Pharma Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.6.3 Taj Pharma Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Taj Pharma Main Business Overview
 - 13.6.5 Taj Pharma Latest Developments
- 13.7 Abbott
 - 13.7.1 Abbott Company Information
 - 13.7.2 Abbott Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.7.3 Abbott Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Abbott Main Business Overview
 - 13.7.5 Abbott Latest Developments
- 13.8 Chengda Pharmaceutical
 - 13.8.1 Chengda Pharmaceutical Company Information

13.8.2 Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications

13.8.3 Chengda Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Chengda Pharmaceutical Main Business Overview

13.8.5 Chengda Pharmaceutical Latest Developments

13.9 Lonza Group

13.9.1 Lonza Group Company Information

13.9.2 Lonza Group Cardiometabolic Disease Drug Product Portfolios and Specifications

13.9.3 Lonza Group Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Lonza Group Main Business Overview

13.9.5 Lonza Group Latest Developments

13.10 Hengtai Chemical

13.10.1 Hengtai Chemical Company Information

13.10.2 Hengtai Chemical Cardiometabolic Disease Drug Product Portfolios and Specifications

13.10.3 Hengtai Chemical Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Hengtai Chemical Main Business Overview

13.10.5 Hengtai Chemical Latest Developments

13.11 Northeast Pharmaceutical

13.11.1 Northeast Pharmaceutical Company Information

13.11.2 Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications

13.11.3 Northeast Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Northeast Pharmaceutical Main Business Overview

13.11.5 Northeast Pharmaceutical Latest Developments

13.12 Biosint

13.12.1 Biosint Company Information

13.12.2 Biosint Cardiometabolic Disease Drug Product Portfolios and Specifications

13.12.3 Biosint Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)

13.12.4 Biosint Main Business Overview

13.12.5 Biosint Latest Developments

13.13 NHU

13.13.1 NHU Company Information

- 13.13.2 NHU Cardiometabolic Disease Drug Product Portfolios and Specifications
- 13.13.3 NHU Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.13.4 NHU Main Business Overview
- 13.13.5 NHU Latest Developments
- 13.14 Kingdomway
 - 13.14.1 Kingdomway Company Information
 - 13.14.2 Kingdomway Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.14.3 Kingdomway Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.14.4 Kingdomway Main Business Overview
 - 13.14.5 Kingdomway Latest Developments
- 13.15 Kaneka
 - 13.15.1 Kaneka Company Information
 - 13.15.2 Kaneka Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.15.3 Kaneka Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.15.4 Kaneka Main Business Overview
 - 13.15.5 Kaneka Latest Developments
- 13.16 Space Biology
 - 13.16.1 Space Biology Company Information
 - 13.16.2 Space Biology Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.16.3 Space Biology Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.16.4 Space Biology Main Business Overview
 - 13.16.5 Space Biology Latest Developments
- 13.17 ZMC
 - 13.17.1 ZMC Company Information
 - 13.17.2 ZMC Cardiometabolic Disease Drug Product Portfolios and Specifications
 - 13.17.3 ZMC Cardiometabolic Disease Drug Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.17.4 ZMC Main Business Overview
 - 13.17.5 ZMC Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cardiometabolic Disease Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Cardiometabolic Disease Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Trimetazidine

Table 4. Major Players of L-carnitine

Table 5. Major Players of Cyclic Adenosine Monophosphate

Table 6. Major Players of Coenzyme Q10

Table 7. Major Players of Others

Table 8. Global Cardiometabolic Disease Drug Sales by Type (2019-2024) & (K Units)

Table 9. Global Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)

Table 10. Global Cardiometabolic Disease Drug Revenue by Type (2019-2024) & (\$ million)

Table 11. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2019-2024)

Table 12. Global Cardiometabolic Disease Drug Sale Price by Type (2019-2024) & (US\$/Unit)

Table 13. Global Cardiometabolic Disease Drug Sale by Application (2019-2024) & (K Units)

Table 14. Global Cardiometabolic Disease Drug Sale Market Share by Application (2019-2024)

Table 15. Global Cardiometabolic Disease Drug Revenue by Application (2019-2024) & (\$ million)

Table 16. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2019-2024)

Table 17. Global Cardiometabolic Disease Drug Sale Price by Application (2019-2024) & (US\$/Unit)

Table 18. Global Cardiometabolic Disease Drug Sales by Company (2019-2024) & (K Units)

Table 19. Global Cardiometabolic Disease Drug Sales Market Share by Company (2019-2024)

Table 20. Global Cardiometabolic Disease Drug Revenue by Company (2019-2024) & (\$ millions)

Table 21. Global Cardiometabolic Disease Drug Revenue Market Share by Company

(2019-2024)

Table 22. Global Cardiometabolic Disease Drug Sale Price by Company (2019-2024) & (US\$/Unit)

Table 23. Key Manufacturers Cardiometabolic Disease Drug Producing Area Distribution and Sales Area

Table 24. Players Cardiometabolic Disease Drug Products Offered

Table 25. Cardiometabolic Disease Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Cardiometabolic Disease Drug Sales by Geographic Region (2019-2024) & (K Units)

Table 29. Global Cardiometabolic Disease Drug Sales Market Share Geographic Region (2019-2024)

Table 30. Global Cardiometabolic Disease Drug Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 31. Global Cardiometabolic Disease Drug Revenue Market Share by Geographic Region (2019-2024)

Table 32. Global Cardiometabolic Disease Drug Sales by Country/Region (2019-2024) & (K Units)

Table 33. Global Cardiometabolic Disease Drug Sales Market Share by Country/Region (2019-2024)

Table 34. Global Cardiometabolic Disease Drug Revenue by Country/Region (2019-2024) & (\$ millions)

Table 35. Global Cardiometabolic Disease Drug Revenue Market Share by Country/Region (2019-2024)

Table 36. Americas Cardiometabolic Disease Drug Sales by Country (2019-2024) & (K Units)

Table 37. Americas Cardiometabolic Disease Drug Sales Market Share by Country (2019-2024)

Table 38. Americas Cardiometabolic Disease Drug Revenue by Country (2019-2024) & (\$ millions)

Table 39. Americas Cardiometabolic Disease Drug Sales by Type (2019-2024) & (K Units)

Table 40. Americas Cardiometabolic Disease Drug Sales by Application (2019-2024) & (K Units)

Table 41. APAC Cardiometabolic Disease Drug Sales by Region (2019-2024) & (K Units)

Table 42. APAC Cardiometabolic Disease Drug Sales Market Share by Region

(2019-2024)

Table 43. APAC Cardiometabolic Disease Drug Revenue by Region (2019-2024) & (\$ millions)

Table 44. APAC Cardiometabolic Disease Drug Sales by Type (2019-2024) & (K Units)

Table 45. APAC Cardiometabolic Disease Drug Sales by Application (2019-2024) & (K Units)

Table 46. Europe Cardiometabolic Disease Drug Sales by Country (2019-2024) & (K Units)

Table 47. Europe Cardiometabolic Disease Drug Revenue by Country (2019-2024) & (\$ millions)

Table 48. Europe Cardiometabolic Disease Drug Sales by Type (2019-2024) & (K Units)

Table 49. Europe Cardiometabolic Disease Drug Sales by Application (2019-2024) & (K Units)

Table 50. Middle East & Africa Cardiometabolic Disease Drug Sales by Country (2019-2024) & (K Units)

Table 51. Middle East & Africa Cardiometabolic Disease Drug Revenue Market Share by Country (2019-2024)

Table 52. Middle East & Africa Cardiometabolic Disease Drug Sales by Type (2019-2024) & (K Units)

Table 53. Middle East & Africa Cardiometabolic Disease Drug Sales by Application (2019-2024) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of Cardiometabolic Disease Drug

Table 55. Key Market Challenges & Risks of Cardiometabolic Disease Drug

Table 56. Key Industry Trends of Cardiometabolic Disease Drug

Table 57. Cardiometabolic Disease Drug Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Cardiometabolic Disease Drug Distributors List

Table 60. Cardiometabolic Disease Drug Customer List

Table 61. Global Cardiometabolic Disease Drug Sales Forecast by Region (2025-2030) & (K Units)

Table 62. Global Cardiometabolic Disease Drug Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 63. Americas Cardiometabolic Disease Drug Sales Forecast by Country (2025-2030) & (K Units)

Table 64. Americas Cardiometabolic Disease Drug Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 65. APAC Cardiometabolic Disease Drug Sales Forecast by Region (2025-2030) & (K Units)

Table 66. APAC Cardiometabolic Disease Drug Annual Revenue Forecast by Region

(2025-2030) & (\$ millions)

Table 67. Europe Cardiometabolic Disease Drug Sales Forecast by Country

(2025-2030) & (K Units)

Table 68. Europe Cardiometabolic Disease Drug Revenue Forecast by Country

(2025-2030) & (\$ millions)

Table 69. Middle East & Africa Cardiometabolic Disease Drug Sales Forecast by Country (2025-2030) & (K Units)

Table 70. Middle East & Africa Cardiometabolic Disease Drug Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 71. Global Cardiometabolic Disease Drug Sales Forecast by Type (2025-2030) & (K Units)

Table 72. Global Cardiometabolic Disease Drug Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 73. Global Cardiometabolic Disease Drug Sales Forecast by Application (2025-2030) & (K Units)

Table 74. Global Cardiometabolic Disease Drug Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 75. Merck Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 76. Merck Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 77. Merck Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 78. Merck Main Business

Table 79. Merck Latest Developments

Table 80. Roche Holding AG Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 81. Roche Holding AG Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 82. Roche Holding AG Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 83. Roche Holding AG Main Business

Table 84. Roche Holding AG Latest Developments

Table 85. Servier Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 86. Servier Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 87. Servier Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 88. Servier Main Business

Table 89. Servier Latest Developments

- Table 90. Qilu Pharmaceutical Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 91. Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 92. Qilu Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 93. Qilu Pharmaceutical Main Business
- Table 94. Qilu Pharmaceutical Latest Developments
- Table 95. Sydler Group Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 96. Sydler Group Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 97. Sydler Group Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 98. Sydler Group Main Business
- Table 99. Sydler Group Latest Developments
- Table 100. Taj Pharma Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 101. Taj Pharma Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 102. Taj Pharma Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 103. Taj Pharma Main Business
- Table 104. Taj Pharma Latest Developments
- Table 105. Abbott Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 106. Abbott Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 107. Abbott Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 108. Abbott Main Business
- Table 109. Abbott Latest Developments
- Table 110. Chengda Pharmaceutical Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 111. Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 112. Chengda Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 113. Chengda Pharmaceutical Main Business
- Table 114. Chengda Pharmaceutical Latest Developments

- Table 115. Lonza Group Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 116. Lonza Group Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 117. Lonza Group Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 118. Lonza Group Main Business
- Table 119. Lonza Group Latest Developments
- Table 120. Hengtai Chemical Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 121. Hengtai Chemical Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 122. Hengtai Chemical Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 123. Hengtai Chemical Main Business
- Table 124. Hengtai Chemical Latest Developments
- Table 125. Northeast Pharmaceutical Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 126. Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 127. Northeast Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 128. Northeast Pharmaceutical Main Business
- Table 129. Northeast Pharmaceutical Latest Developments
- Table 130. Biosint Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 131. Biosint Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 132. Biosint Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 133. Biosint Main Business
- Table 134. Biosint Latest Developments
- Table 135. NHU Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors
- Table 136. NHU Cardiometabolic Disease Drug Product Portfolios and Specifications
- Table 137. NHU Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 138. NHU Main Business
- Table 139. NHU Latest Developments
- Table 140. Kingdomway Basic Information, Cardiometabolic Disease Drug

Manufacturing Base, Sales Area and Its Competitors

Table 141. Kingdomway Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 142. Kingdomway Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 143. Kingdomway Main Business

Table 144. Kingdomway Latest Developments

Table 145. Kaneka Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 146. Kaneka Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 147. Kaneka Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 148. Kaneka Main Business

Table 149. Kaneka Latest Developments

Table 150. Space Biology Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 151. Space Biology Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 152. Space Biology Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 153. Space Biology Main Business

Table 154. Space Biology Latest Developments

Table 155. ZMC Basic Information, Cardiometabolic Disease Drug Manufacturing Base, Sales Area and Its Competitors

Table 156. ZMC Cardiometabolic Disease Drug Product Portfolios and Specifications

Table 157. ZMC Cardiometabolic Disease Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 158. ZMC Main Business

Table 159. ZMC Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Cardiometabolic Disease Drug
- Figure 2. Cardiometabolic Disease Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Cardiometabolic Disease Drug Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Cardiometabolic Disease Drug Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Cardiometabolic Disease Drug Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Cardiometabolic Disease Drug Sales Market Share by Country/Region (2023)
- Figure 10. Cardiometabolic Disease Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Trimetazidine
- Figure 12. Product Picture of L-carnitine
- Figure 13. Product Picture of Cyclic Adenosine Monophosphate
- Figure 14. Product Picture of Coenzyme Q10
- Figure 15. Product Picture of Others
- Figure 16. Global Cardiometabolic Disease Drug Sales Market Share by Type in 2023
- Figure 17. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2019-2024)
- Figure 18. Cardiometabolic Disease Drug Consumed in Online Sales
- Figure 19. Global Cardiometabolic Disease Drug Market: Online Sales (2019-2024) & (K Units)
- Figure 20. Cardiometabolic Disease Drug Consumed in Hospital
- Figure 21. Global Cardiometabolic Disease Drug Market: Hospital (2019-2024) & (K Units)
- Figure 22. Cardiometabolic Disease Drug Consumed in Clinic
- Figure 23. Global Cardiometabolic Disease Drug Market: Clinic (2019-2024) & (K Units)
- Figure 24. Cardiometabolic Disease Drug Consumed in Retail Pharmacy
- Figure 25. Global Cardiometabolic Disease Drug Market: Retail Pharmacy (2019-2024) & (K Units)
- Figure 26. Cardiometabolic Disease Drug Consumed in Others
- Figure 27. Global Cardiometabolic Disease Drug Market: Others (2019-2024) & (K Units)

Figure 28. Global Cardiometabolic Disease Drug Sale Market Share by Application (2023)

Figure 29. Global Cardiometabolic Disease Drug Revenue Market Share by Application in 2023

Figure 30. Cardiometabolic Disease Drug Sales by Company in 2023 (K Units)

Figure 31. Global Cardiometabolic Disease Drug Sales Market Share by Company in 2023

Figure 32. Cardiometabolic Disease Drug Revenue by Company in 2023 (\$ millions)

Figure 33. Global Cardiometabolic Disease Drug Revenue Market Share by Company in 2023

Figure 34. Global Cardiometabolic Disease Drug Sales Market Share by Geographic Region (2019-2024)

Figure 35. Global Cardiometabolic Disease Drug Revenue Market Share by Geographic Region in 2023

Figure 36. Americas Cardiometabolic Disease Drug Sales 2019-2024 (K Units)

Figure 37. Americas Cardiometabolic Disease Drug Revenue 2019-2024 (\$ millions)

Figure 38. APAC Cardiometabolic Disease Drug Sales 2019-2024 (K Units)

Figure 39. APAC Cardiometabolic Disease Drug Revenue 2019-2024 (\$ millions)

Figure 40. Europe Cardiometabolic Disease Drug Sales 2019-2024 (K Units)

Figure 41. Europe Cardiometabolic Disease Drug Revenue 2019-2024 (\$ millions)

Figure 42. Middle East & Africa Cardiometabolic Disease Drug Sales 2019-2024 (K Units)

Figure 43. Middle East & Africa Cardiometabolic Disease Drug Revenue 2019-2024 (\$ millions)

Figure 44. Americas Cardiometabolic Disease Drug Sales Market Share by Country in 2023

Figure 45. Americas Cardiometabolic Disease Drug Revenue Market Share by Country (2019-2024)

Figure 46. Americas Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)

Figure 47. Americas Cardiometabolic Disease Drug Sales Market Share by Application (2019-2024)

Figure 48. United States Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 49. Canada Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 50. Mexico Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 51. Brazil Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$

millions)

Figure 52. APAC Cardiometabolic Disease Drug Sales Market Share by Region in 2023

Figure 53. APAC Cardiometabolic Disease Drug Revenue Market Share by Region (2019-2024)

Figure 54. APAC Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)

Figure 55. APAC Cardiometabolic Disease Drug Sales Market Share by Application (2019-2024)

Figure 56. China Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 57. Japan Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 58. South Korea Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 59. Southeast Asia Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 60. India Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 61. Australia Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 62. China Taiwan Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 63. Europe Cardiometabolic Disease Drug Sales Market Share by Country in 2023

Figure 64. Europe Cardiometabolic Disease Drug Revenue Market Share by Country (2019-2024)

Figure 65. Europe Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)

Figure 66. Europe Cardiometabolic Disease Drug Sales Market Share by Application (2019-2024)

Figure 67. Germany Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 68. France Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 69. UK Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 70. Italy Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 71. Russia Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 72. Middle East & Africa Cardiometabolic Disease Drug Sales Market Share by Country (2019-2024)

Figure 73. Middle East & Africa Cardiometabolic Disease Drug Sales Market Share by Type (2019-2024)

Figure 74. Middle East & Africa Cardiometabolic Disease Drug Sales Market Share by Application (2019-2024)

Figure 75. Egypt Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 76. South Africa Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 77. Israel Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 78. Turkey Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 79. GCC Countries Cardiometabolic Disease Drug Revenue Growth 2019-2024 (\$ millions)

Figure 80. Manufacturing Cost Structure Analysis of Cardiometabolic Disease Drug in 2023

Figure 81. Manufacturing Process Analysis of Cardiometabolic Disease Drug

Figure 82. Industry Chain Structure of Cardiometabolic Disease Drug

Figure 83. Channels of Distribution

Figure 84. Global Cardiometabolic Disease Drug Sales Market Forecast by Region (2025-2030)

Figure 85. Global Cardiometabolic Disease Drug Revenue Market Share Forecast by Region (2025-2030)

Figure 86. Global Cardiometabolic Disease Drug Sales Market Share Forecast by Type (2025-2030)

Figure 87. Global Cardiometabolic Disease Drug Revenue Market Share Forecast by Type (2025-2030)

Figure 88. Global Cardiometabolic Disease Drug Sales Market Share Forecast by Application (2025-2030)

Figure 89. Global Cardiometabolic Disease Drug Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Cardiometabolic Disease Drug Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G339A3A62116EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G339A3A62116EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970